Sequence: Ac-Tyr-Lys-Leu-Dpg-Leu-Lys-Leu-Dpg-Leu-Lys-Dpg-Leu-Lys-Leu-Dpg-Leu-Lys-NH2
| Experiment Id | EXP001531 |
|---|---|
| Paper | An Amphipathic Structure of a Dipropylglycine-Containing Helical Peptide with Sufficient Length Enab |
| Peptide | Pep4 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 3.4 µM (for N/P=4 with 100 nM siRNA) |
| Rna Concentration | 100 nM (Luc or Scr siRNA); 100 nM Alexa488-siRNA for uptake assay |
| Mixing Ratio | N/P = 4 (amino/guanidino groups : siRNA phosphates) |
| Formulation Format | electrostatic peptide/siRNA complexes (CPP nanoparticles) |
| Formulation Components | Pep4 + siRNA (Luc or Scr) / Alexa488-siRNA (uptake) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Huh-7-Luc (luciferase-expressing human hepatoma cells; 10% FBS media) |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake (flow cytometry + fluorescence microscopy) and RNAi (luciferase assay, 24 h) |
| Output Value | ~70% luciferase knockdown at N/P=4 and ~85% at N/P=8 vs Scr control (24 h). |
| Output Units | |
| Output Notes | Highest Alexa488-siRNA uptake by flow cytometry; bright intracellular signals by microscopy at N/P=4. RNAi measured in 10% FBS at 24 h; Lipofectamine 3000 ineffective under these conditions. |
| Toxicity Notes | Negligible cytotoxicity at active conditions (effective knockdown with acceptable viability). |
| Curation Notes |